We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
-9.15%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.68B
AUM Growth
-$780M
(-32%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-14.17%
Top 10 Holdings %
Top 10 Hldgs %
50.05%
Holding
96
New
8
Increased
9
Reduced
34
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beam Therapeutics
BEAM
|
+$34.2M |
| 2 |
VERV
Verve Therapeutics
VERV
|
+$16.8M |
| 3 |
VTYX
Ventyx Biosciences
VTYX
|
+$14.9M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$14M |
| 5 |
Tango Therapeutics
TNGX
|
+$12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$50.6M |
| 2 |
AGEN
Agenus
AGEN
|
+$25.2M |
| 3 |
Revolution Medicines
RVMD
|
+$20.1M |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$18.7M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$17.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Erasca
ERAS
$6.15B
| $164M | 9.74% |
10,505,550
| – | – |
|
|
TPTX
2
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $144M | 8.58% |
3,025,000
+182,703
| +6% | +$8.17M |
|
3
Design Therapeutics
DSGN
$751M
| $116M | 6.93% |
5,440,453
+75,603
| +1% | +$1.3M |
|
|
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $73.1M | 4.35% |
1,848,024
| – | – |
|
|
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $66M | 3.92% |
4,639,995
-80,500
| -2% | -$1.39M |
|
6
Monte Rosa Therapeutics
GLUE
$1.82B
| $61.3M | 3.65% |
3,002,199
-100,000
| -3% | -$2.09M |
|
|
7
Revolution Medicines
RVMD
$38.5B
| $61.2M | 3.64% |
2,431,852
-712,848
| -23% | -$20.1M |
|
8
Edgewise Therapeutics
EWTX
$4.28B
| $54.5M | 3.24% |
3,565,901
+194,987
| +6% | +$3.51M |
|
|
9
Tango Therapeutics
TNGX
$4.21B
| $53.1M | 3.16% |
4,899,185
+1,000,000
| +26% | +$12M |
|
|
RNAM
10
DELISTED
Avidity Biosciences
RNAM
| $47.8M | 2.84% |
2,012,115
-150,000
| -7% | -$3.58M |
|
|
VERV
11
DELISTED
Verve Therapeutics
VERV
| $40.9M | 2.43% |
1,109,224
+400,000
| +56% | +$16.8M |
|
|
12
Beam Therapeutics
BEAM
$2.68B
| $39.8M | 2.37% |
500,000
+400,000
| +400% | +$34.2M |
|
13
Immuneering
IMRX
$262M
| $37.2M | 2.21% |
2,302,626
+50,000
| +2% | +$1.22M |
|
14
BioAtla
BCAB
$5.34M
| $33M | 1.96% |
33,622
-2,689
| -7% | -$3.44M |
|
15
Cytokinetics
CYTK
$10.6B
| $31.9M | 1.9% |
700,000
-300,000
| -30% | -$11.6M |
|
16
Tarsus Pharmaceuticals
TARS
$2.55B
| $31.6M | 1.88% |
1,403,331
-41,500
| -3% | -$1.08M |
|
|
RAIN
17
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $30M | 1.78% |
2,326,660
| – | – |
|
|
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
| $29.6M | 1.76% |
625,000
-300,000
| -32% | -$11.8M |
|
19
Stoke Therapeutics
STOK
$1.84B
| $28.4M | 1.69% |
1,182,362
-95,914
| -8% | -$2.29M |
|
|
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
| $28M | 1.67% |
2,489,894
+762,621
| +44% | +$10.3M |
|
21
BridgeBio Pharma
BBIO
$16.4B
| $27.8M | 1.66% |
1,668,909
-100,000
| -6% | -$4.23M |
|
22
Biomea Fusion
BMEA
$88.2M
| $23.6M | 1.41% |
3,170,872
| – | – |
|
|
AMAM
23
DELISTED
Ambrx Biopharma Inc
AMAM
| $22.5M | 1.34% |
2,486,386
| – | – |
|
|
JBIO
24
Jade Biosciences
JBIO
$1.18B
| $21.6M | 1.28% |
52,305
-5,715
| -10% | -$2.89M |
|
|
25
Olema Pharmaceuticals
OLMA
$977M
| $20.3M | 1.21% |
2,169,871
-903,614
| -29% | -$18.7M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q4 2021 Portfolio in Review
As of Q4 2021, Cormorant Asset Management held 96 positions worth $1.68B, down 32% from $2.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Cormorant Asset Management withdrew a net $238M in Q4 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was Agenus, an estimated $25.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Ventyx Biosciences worth $15.1M.
- Cormorant Asset Management's largest Q4 2021 buy was Ventyx Biosciences: 785,303 shares worth $15.1M.
- Cormorant Asset Management added most to Beam Therapeutics in Q4 2021, an estimated $34.2M increase.
- Cormorant Asset Management's biggest Q4 2021 reduction was Atea Pharmaceuticals, cutting an estimated $50.6M.
- Cormorant Asset Management fully exited Agenus in Q4 2021, selling an estimated $25.2M.
- Cormorant Asset Management's ten largest holdings make up 50% of its $1.68B portfolio in Q4 2021.
- Cormorant Asset Management opened 8 new positions and closed 18 in Q4 2021.
- Cormorant Asset Management's portfolio value fell 32% quarter-over-quarter to $1.68B.
Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.